74
STAR-ADVERTISER / 2016
The University of Hawaii John A. Burns School of Medicine is seeking recently diagnosed COVID-19 patients for a 21-day study.
The University of Hawaii John A. Burns School of Medicine is seeking recently diagnosed COVID-19 patients for a 21-day study.
The study is led by Cecilia Shikuma, JABSOM professor of medicine and lead investigator, and researchers hope to find evidence that taking telmisartan, a medication used for blood pressure control, will prevent harmful effects of the virus.
Participants will be placed on either a placebo (sugar pill) or telmisartan.
“Finding an effective therapy for COVID-19 is very important. In fact, it may be more important or as important as finding a vaccine. Because you do not want to get ill and end up in the hospital,” Shikuma said in a statement.
Shikuma recommends that those who wish to participate in the trial call as soon as they are diagnosed with COVID-19.
“One of the good things about entering a clinical trial is that your clinical status will be monitored by a group of very experienced doctors and nurses,” she said.
For more information, contact Cris Milne at 692-1335 or email cmilne@hawaii.edu.
By participating in online discussions you acknowledge that you have agreed to the Terms of Service. An insightful discussion of ideas and viewpoints is encouraged, but comments must be civil and in good taste, with no personal attacks. If your comments are inappropriate, you may be banned from posting. Report comments if you believe they do not follow our guidelines.
Having trouble with comments? Learn more here.